Skip to main content

Table 2 Disease severity and outcomes of patients without or with hypouricemia

From: Serum uric acid, disease severity and outcomes in COVID-19

 

Discovery cohort, n = 192

Validation cohort, n = 325

 

No hypouricemia,

n = 153

Hypouricemia,

n = 39

P

No hypouricemia,

n = 262

Hypouricemia,

n = 63

P

Disease severity

      

Classification—no. (%)

  

 < 0.001

  

 < 0.001

 Mild

13 (9)

1 (3)

 

21 (8)

3 (5)

 

 Moderate

32 (21)

3 (8)

 

68 (26)

10 (16)

 

 Severe

88 (58)

11 (28)

 

154 (59)

21 (33)

 

 Critical

20 (13)

24 (62)

 

19 (7)

29 (46)

 

Peak hsCRP, median (IQR), mg/l

123 (65–221)

266 (114–349)

 < 0.001

102 (54–161)

205 (106–302)

 < 0.001

Nadir lymph. count, median (IQR), µl−1

690 (440–1000)

410 (210–770)

 < 0.001

785 (560–1110)

440 (280–640)

 < 0.001

Peak LDH, median (IQR), IU/l

404 (318–515)

559 (456–733)

 < 0.001

384 (293–479)

514 (343–746)

 < 0.001

Outcomes

      

Death—no. (%)

31 (20)

13 (33)

0.1

27 (10)

22 (35)

 < 0.001

Mechanical ventilation—no. (%)

10 (7)

22 (56)

 < 0.001

4 (2)

25 (40)

 < 0.001

Acute kidney injury—no. (%)

17 (11)

5 (13)

0.8

13 (5)

19 (31)

 < 0.001

Kidney replacement therapy—no. (%)

4 (3)

2 (5)

0.4

3 (1)

7 (11)

 < 0.001

Hospital LOS, median (IQR), days

11 (6–16)

20 (14–39)

 < 0.001

8 (4–12)

15 (8–38)

 < 0.001

  1. Continuous variables are expressed as median and interquartile range (IQR) and categorical variables as numbers (no.) and percentages (%)
  2. hsCRP, highly sensitive C-reactive protein; lymph., lymphocytes; LDH, lactate dehydrogenase; LOS, length of stay